More than two decades of clinical data research has culminated to bring about a future where a patient’s asthma exacerbations could be predicted years in advance.
Results from the study, “The Ratio of Circulatory Levels of Sphingolipids to Steroids Predicts Asthma Exacerbations,” suggest that a simple blood test measuring the ratio of two types of circulating molecules — sphingolipids and steroids — may accurately predict which asthma patients are most likely to suffer severe exacerbations over the next five years. The research was published in Nature Communications.
The research, which drew from three major asthma cohorts totaling 2,513 adults, represents one of the most comprehensive efforts to date to identify reliable biomarkers for asthma instability. According to the study’s authors, clinicians have previously lacked a robust laboratory tool to identify patients at high risk of future exacerbations, which can lead to hospitalizations, reduced lung function and lifelong respiratory complications.
Asthma is notoriously heterogeneous: two patients with similar symptoms can experience very different long‑term outcomes, the research explains. Current clinical predictors, such as lung function tests, blood eosinophil counts or prior exacerbation history, often fall short in forecasting who will deteriorate.
The new study addressed this gap by integrating global metabolomics profiling with targeted biochemical assays. Researchers found that the sphingolipids-to-steroids ratio in the blood strongly and consistently predicted five‑year exacerbation risk. These ratios, derived from 21 specific metabolite pairs, outperformed all conventional clinical markers.
In discovery analyses, the prediction model achieved an area‑under‑the‑curve (AUC) score of 0.90, replicated at 0.89 in independent cohorts — an unusually high level of predictive accuracy for asthma research.
Sphingolipids and steroids each play critical roles in asthma biology:
- Sphingolipids help regulate airway inflammation and immune signaling. Past studies show that disruptions in sphingolipid pathways are linked to abnormal lung development and heightened inflammatory responses.
- Steroids, including natural corticosteroids, regulate inflammation and form the basis of inhaled corticosteroid (ICS) treatments. Abnormal steroid levels — whether from biological deficiency or medication‑related suppression — can worsen asthma control.
The study found that the ratio between these two pathways provided far more predictive power than either category of molecule alone. Individual ratios could distinguish between “high‑risk” and “low‑risk” patients up to a year before an exacerbation occurred.
Researchers emphasized that the metabolites involved are abundant, stable and inexpensive to measure — key criteria for translating laboratory findings into real‑world clinical assays.
If validated further, the authors said a blood test based on these ratios could revolutionize asthma management by:
- Identifying high‑risk patients before clinical symptoms worsen
- Guiding earlier use of advanced therapies, such as biologics
- Helping clinicians tailor steroid dosing more precisely
- Offering a cost‑effective alternative to current biomarker strategies
Beyond exacerbation risk, specific metabolite ratios also showed targeted associations with lung function decline and other asthma traits, suggesting potential use in subtype classification.
The authors noted several limitations, including differences in metabolomics platforms across cohorts and variability in electronic medical record (EMR) data. The strong cross‑cohort replication underscores the robustness of their approach.
The next steps, they noted, include expanding targeted assays to additional metabolic pathways and further refining predictive models to integrate more clinical data.
The study’s authors said that as asthma care shifts toward personalized treatment, this work demonstrates how metabolomics can bridge the gap between laboratory research and practical clinical tools. Sphingolipid‑to‑steroid ratios could pave the way for earlier intervention — and better outcomes — for millions of patients living with asthma, they concluded.
